SCHEMBL6032172

SCHEMBL6032172

CCON1C(=O)SC(Cc2ccccc2)C1=O

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.53
KDM4E B2RXH2 1/20 0.53
PPARG P37231 5/20 0.43
MAOB P27338 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
CA2 P00918 1/20 0.40
POLB P06746 1/20 0.40
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
LMNA P02545 4/20 0.39
GAA P10253 1/20 0.38
THRB P10828 1/20 0.38
KMT2A Q03164 1/20 0.37
MCL1 Q07820 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7469293 0.85 MAPT (0.56) MAPTKDM4EPPARGMAOBCYP1A2
SCHEMBL8486948 0.79 MAPT (0.44) MAPTKDM4EPPARGMAOBCYP1A2
SCHEMBL8523887 0.77 MAPT (0.43) MAPTKDM4EPPARGMAOBCYP1A2
SCHEMBL8660907 0.77 PPARG (0.53) MAPTKDM4EPPARGCYP1A2CYP3A4
SCHEMBL8472101 0.77 MAPT (0.41) MAPTKDM4EPPARGMAOBCYP1A2
SCHEMBL8687360 0.77 PPARG (0.48) MAPTKDM4EPPARGCYP1A2CYP3A4
SCHEMBL8524315 0.77 FFAR1 (0.53) MAPTKDM4EPPARGCYP1A2CYP3A4
SCHEMBL8664520 0.75 PPARG (0.56) MAPTKDM4EPPARGCYP1A2CYP3A4
SCHEMBL8484201 0.75 SIGMAR1 (0.45) MAPTKDM4E
SCHEMBL8659791 0.75 MAPT (0.44) MAPTKDM4EPPARGCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060052627-A1 Novel modulators of the PPAR-type receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-03-09 US disclosed
EP-0555249-A1 THIAZOLIDINEDIONE DERIVATIVES BEECHAM GROUP plc (GB) 1993-08-18 EP disclosed
US-4725610-A TREATMENT OF HYPERLIPEMIA AND DIABETES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1988-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052627-A1 Novel modulators of the PPAR-type receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARD, PPARA MAPT 3674/4885KDM4E 3115/4885PPARG 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.